Yuen-Fen TanLing‐Wei HiiWei‐Meng LimSoon-Keng CheongChee‐Onn LeongMaxine Swee‐Li YeeChun‐Wai Mai
Small interfering RNAs (siRNA) technology has emerged as a promising therapeutic tool for human health conditions like cancer due to its ability to regulate gene silencing. Despite FDA-approved, their delivery remains localized and limiting their systemic use. This study used single-walled carbon nanotubes (SWNTs) functionalized with polyethylene glycolated (PEGylated) phospholipids (PL-PEG) derivatives for systemic siRNA delivery. We developed an siRNA systemic delivery vehicle (SWNT-siRNA) by conjugating SWNT functionalized with PL-PEG containing either amine (PA) or maleimide (MA). The functionalized SWNT with a lower molecular weight of PA produced the SWNT-siRNA conjugate system with the highest stability and high siRNA loading quantity. The system delivered siRNA to a panel of tumour cell lines of different organs (i.e. HeLa, H1299 and MCF-7) and a non-cancerous human embryonic kidney 293 cells (HEK293T) with high biocompatibility and low toxicity. The cellular uptake of SWNT-siRNA conjugates by epithelial cells was found to be energy dependent. Importantly, the presence of P-glycoprotein, a marker for drug resistance, did not inhibit SWNT-mediated siRNA delivery. Mouse xenograft model further confirmed the potential of SWNT-siRNA conjugates with a significant gene knock-down without signs of acute toxicity. These findings pave the way for potential gene therapy applications using SWNTs as delivery vehicles.
Yang TanSinyoung CheongChee‐Onn Leong
Yang TanSoshan CheongChee‐Onn Leong
Cristiano Sacchetti (1700917)Ru Liu-Bryan (814503)Andrea Magrini (1700920)Nicola Rosato (1512250)Nunzio Bottini (518800)Massimo Bottini (1700923)
Cristiano SacchettiRu Liu‐BryanAndrea MagriniNicola RosatoNunzio BottiniMassimo Bottini
Amir K. VarkouhiStéphanie FoillardTwan LammersRaymond M. SchiffelersEric DorisWim E. HenninkGert Storm